MNDL Bio

Company Overview

Snapshot

Founded in June 2023 by Steve Grun, Tamir Tuller, and Eran Miller, MNDL Bio operates with 1–10 employees. The company has raised $2.1 million across two funding rounds from two investors. In January 2024, MNDL Bio secured funding from Earth & Beyond Ventures and CPT Capital.

Business overview

MNDL Bio develops solutions for optimizing gene expression in cells to enhance protein production yield. The company leverages advanced algorithms, patented methods, Artificial Intelligence (AI), and Machine Learning (ML) based on genomic Big Data. MNDL Bio's technology aims to increase the efficiency, productivity, and cost-effectiveness of biological systems, with applications spanning various sectors including alternative protein sources, precision fermentation, and bio-based materials. The company operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering, and is also relevant to Climate Tech through sustainable materials and circularity.

Strategic signal

In March 2025, MNDL Bio received an award for the most innovative biotech solution in the Middle East. This recognition highlights the company's cutting-edge approach to gene optimization and its potential to significantly impact the biotechnology landscape, signaling strong validation of its technological innovation and market relevance to investors.

Company Intelligence Q&A

What is MNDL Bio's core technology?

MNDL Bio utilizes Artificial Intelligence (AI) and Machine Learning (ML) based on genomic Big Data, coupled with advanced algorithms and patented methods, to optimize gene expression in cells for increased protein production yield.

When was MNDL Bio founded and by whom?

MNDL Bio was founded in June 2023 by co-founders Steve Grun, Tamir Tuller, and Eran Miller.

What significant recognition did MNDL Bio receive in March 2025?

In March 2025, MNDL Bio won an award for the most innovative biotech solution in the Middle East, as reported by www.jpost.com.

Which investors participated in MNDL Bio's January 2024 funding round?

In January 2024, MNDL Bio received funding from Earth & Beyond Ventures and CPT Capital.

What is MNDL Bio's relevance to climate tech?

MNDL Bio's solution contributes to climate tech by promoting alternative protein sources, enhancing precision fermentation for sustainable compounds, and enabling the production of bio-based materials like bioplastics, which reduce reliance on petroleum-based products.